Trends of the WorldDigital Therapeutics FDA Approval
The FDA approval of an entirely new drug class for ADHD — the first NDSRI — opens a differentiated commercial pathway in a market exceeding $20 billion annually. Patients who fail or cannot tolerate stimulants or existing non-stimulants now have a mechanistically distinct option. Otsuka gains first-mover exclusivity in this pharmacological category, creating significant pricing power and prescription growth potential in both adult and pediatric segments.
This is one of 6 signals scored across 21 industries in our latest scan.
See them all free →Since we flagged this
First flagged
25 March 2026 · score 7.0/10
Score trajectory (10 runs, live record)
Corroborating sources since flagging
129
The signal strengthens if
- Major U.S. pharmacy benefit managers (CVS Caremark, Express Scripts, OptumRx) add Mounjaro's CV indication to Tier 2 or preferred formulary status within 12 months of approval.
- Lilly reports Mounjaro quarterly revenue exceeding $5 billion in any reported quarter following the CV label expansion, attributable in part to new cardiology prescriptions.
The signal weakens if
- A head-to-head cardiovascular outcomes trial published in a peer-reviewed journal shows a GLP-1-only competitor (e.g., semaglutide) achieving non-inferior MACE reduction to tirzepatide in type 2 diabetes patients.
- CMS or a major insurer issues a national coverage determination explicitly excluding Mounjaro's CV indication from reimbursement for Medicare Part D beneficiaries.
How the evidence accumulated
Digital Therapeutics FDA Approval
Since 25 March 2026
How the evidence accumulated — 9 findings and 129 corroborating sources since 25 March 2026.
Create a free account to see the timeline.
Create free accountScores are model-generated assessments of accumulated evidence and may be incomplete or wrong. Provided for informational purposes only; not investment advice.
Sources
Scored from 9 independent sources.
Members also get the underlying papers and reports, the related news feed and the regulatory register for this industry. Open the sources free →
More in Healthcare
Other trends the engine is currently tracking in this industry.
Start reading the full feed
A weekly sample of what the engine finds.
- 3 scored signals per week, sources included — no card required
- Preview of top trends
- Basic industry labels
- Sunday Signals (weekly) teaser
Disclaimer: The information provided on this page is for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Stock data shown is illustrative and may not reflect real-time prices. Always conduct your own research and consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.